Biotech Co. Must Face Securities Suit Over FDA Rejection
A New York federal judge on Tuesday rejected a bid from Acer Therapeutics to reverse his decision to allow a proposed securities class action to continue as it alleges the biotech...To view the full article, register now.
Already a subscriber? Click here to view full article